Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 0.16 and has seen 1.11 million shares traded in the last trading session. The company, currently valued at $518.36M, closed the last trade at $7.26 per share which meant it lost -$0.19 on the day or -2.55% during that session. The ESPR stock price is -80.99% off its 52-week high price of $13.14 and 54.82% above the 52-week low of $3.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.27 million shares traded. The 3-month trading volume is 1.01 million shares.
The consensus among analysts is that Esperion Therapeutics Inc. (ESPR) is a Hold stock at the moment, with a recommendation rating of 2.70. 3 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 11 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.93.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Sporting -2.55% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 09/20/22 when the ESPR stock price touched $7.26 or saw a rise of 4.85%. Year-to-date, Esperion Therapeutics Inc. shares have moved 45.20%, while the 5-day performance has seen it change 2.98%. Over the past 30 days, the shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) have changed -1.76%. Short interest in the company has seen 12.13 million shares shorted with days to cover at 15.2.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Figures show that Esperion Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 31.28% over the past 6 months, with this year growth rate of 59.08%, compared to 11.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 44.30% and 65.30% for the next quarter. Revenue growth from the last financial year stood is estimated to be 4.30%.
9 analysts offering their estimates for the company have set an average revenue estimate of $18.71 million for the current quarter. 9 have an estimated revenue figure of $20.8 million for the next quarter concluding in Sep 2022.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -22.90% over the past 5 years. Earnings growth for 2022 is a modest -78.20% while over the next 5 years, the company’s earnings are expected to increase by 16.90%.
Esperion Therapeutics Inc. is expected to release its next earnings report between May 02 and May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
Insiders own 0.97% of the company shares, while shares held by institutions stand at 84.37% with a share float percentage of 85.20%. Investors are also buoyed by the number of investors in a company, with Esperion Therapeutics Inc. having a total of 183 institutions that hold shares in the company. The top two institutional holders are Wasatch Advisors Inc with over 8.15 million shares worth more than $37.8 million. As of Mar 30, 2022, Wasatch Advisors Inc held 12.93% of shares outstanding.
The other major institutional holder is Deep Track Capital, LP, with the holding of over 6.0 million shares as of Mar 30, 2022. The firm’s total holdings are worth over $27.84 million and represent 9.52% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. As of Mar 30, 2022, the former fund manager holds about 3.39% shares in the company for having 2.14 million shares of worth $9.91 million while later fund manager owns 1.66 million shares of worth $7.69 million as of Mar 30, 2022, which makes it owner of about 2.63% of company’s outstanding stock.